Beda Joos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3871723/publications.pdf

Version: 2024-02-01

56 papers	3,548 citations	109321 35 h-index	144013 57 g-index
59 all docs	59 docs citations	59 times ranked	4043 citing authors

#	Article	IF	Citations
1	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. Viruses, 2022, 14, 406.	3.3	1
2	Reply to correspondence â€˜Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a â€œstochasticâ€•processâ€™ by Gonzalez et al., Retrovirology 2017. Retrovirology, 2017, 14, 14.	2.0	3
3	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	2.0	45
4	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. PLoS ONE, 2014, 9, e114111.	2.5	17
5	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. Nucleic Acids Research, 2014, 42, e115-e115.	14.5	126
6	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. PLoS Computational Biology, 2014, 10, e1003871.	3.2	19
7	24 Hours in the Life of HIV-1 in a T Cell Line. PLoS Pathogens, 2013, 9, e1003161.	4.7	134
8	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	4.0	35
9	Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. PLoS ONE, 2013, 8, e74249.	2.5	55
10	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	8.9	206
11	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology, 2012, 9, 27.	2.0	39
12	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. Antiviral Therapy, 2011, 16, 535-545.	1.0	77
13	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2011, 203, 791-797.	4.0	9
14	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases, 2011, 53, 1271-1279.	5.8	84
15	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	5.8	127
16	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	2.5	46
17	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. Aids, 2010, 24, 1177-1183.	2.2	62
18	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 2010, 165, 151-160.	2.1	33

#	Article	IF	Citations
19	Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 2010, 10, 365-372.	2.3	2
20	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. PLoS ONE, 2010, 5, e13310.	2.5	84
21	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology, 2008, 5, 107.	2.0	44
22	In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers. Journal of Virology, 2008, 82, 1591-1599.	3.4	50
23	HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16725-16730.	7.1	273
24	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. Journal of Virology, 2007, 81, 8793-8808.	3.4	85
25	Positive In Vivo Selection of the HIVâ€1 Envelope Protein gp120 Occurs at Surfaceâ€Exposed Regions. Journal of Infectious Diseases, 2007, 196, 313-320.	4.0	36
26	Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T Lymphocytes. Journal of Virology, 2007, 81, 9693-9706.	3.4	72
27	Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection. Journal of Virology, 2007, 81, 11016-11031.	3.4	111
28	HIV replication elicits little cytopathic effects in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. Journal of Medical Virology, 2006, 78, 1141-1146.	5.0	12
29	Equal Amounts of Intracellular and Virionâ€Enclosed Hepatitis C Virus RNA Are Associated with Peripheralâ€Blood Mononuclear Cells In Vivo. Journal of Infectious Diseases, 2006, 194, 1713-1723.	4.0	25
30	Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrobial Agents and Chemotherapy, 2006, 50, 1773-1779.	3.2	63
31	Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine, 2005, 11, 615-622.	30.7	468
32	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. Journal of Virology, 2005, 79, 9026-9037.	3.4	40
33	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. Journal of Virology, 2005, 79, 8454-8469.	3.4	76
34	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 250-256.	2.1	23
35	Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIVâ€1 RNA Encodingnef. Journal of Infectious Diseases, 2004, 190, 1979-1988.	4.0	56
36	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids, 2004, 18, 1951-1953.	2.2	73

#	Article	IF	Citations
37	Attenuated and Nonproductive Viral Transcription in the Lymphatic Tissue of HIVâ€1â€“Infected Patients Receiving Potent Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 189, 273-285.	4.0	37
38	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology, 2004, 326, 113-129.	2.4	76
39	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection. Journal of Virology, 2003, 77, 13146-13155.	3.4	54
40	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. Journal of Infectious Diseases, 2003, 188, 1433-1443.	4.0	121
41	HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids, 2003, 17, 195-199.	2.2	82
42	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	1.0	13
43	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	1.0	23
44	Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antiviral Therapy, 2002, 7, 91-103.	1.0	36
45	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. Antiviral Therapy, 2002, 7, 91-103.	1.0	62
46	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	2.1	12
47	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	2.1	46
48	Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1135-1140.	1.1	52
49	Transient rebound of plasma HIV-1 RNA is not followed by repopulation of the lymphoid compartment with HIV-1-infected cells. Aids, 2000, 14, 752-754.	2.2	3
50	Covalent Attachment of Hybridizable Oligonucleotides to Glass Supports. Analytical Biochemistry, 1997, 247, 96-101.	2.4	116
51	The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. Journal of Antimicrobial Chemotherapy, 1995, 36, 137-155.	3.0	20
52	Long term accuracy of fluorescence polarization immunoassays for gentamicin, tobramycin, netilmicin and vancomycin. Journal of Antimicrobial Chemotherapy, 1989, 24, 797-803.	3.0	9
53	Identification of fluorescent glycopeptide derivatives by two consecutive high pressure liquid chromatographic procedures.. Journal of Antibiotics, 1988, 41, 302-307.	2.0	5
54	Stoffwechselprodukte von Mikroorganismen. 218. Mitteilung. Versuche zur StrukturaufklÃrung von Niphimycin, 1. Teil. Reinigung und Charakterisierung der Niphimycine IÎ± und IÎ² sowie Abbau mit SalpetersÃure. Helvetica Chimica Acta, 1983, 66, 92-117.	1.6	38

#	Article	IF	Citations
55	Stoffwechselprodukte von Mikroorganismen. 219. Mitteilung. Versuche zur StrukturaufklÃrung von Niphimycin, 2. Teil. Die Konstitution von Desmalonyl-niphimycin I. Helvetica Chimica Acta, 1983, 66, 226-258.	1.6	21
56	Stoffwechselprodukte von Mikroorganismen. 190. Mitteilung. Ãœber das 4-Oxo-homotyrosin, ein Abbauprodukt des Echinocandins B. Helvetica Chimica Acta, 1980, 63, 250-254.	1.6	6